Boehringer buys Abexxa, bolstering its immuno-oncology pipelineBoehringer Ingelheim has agreed to buy US biotech Abexxa Biologics, its second acquisition in the cancer immunotherapy area Share XBoehringer buys Abexxa, bolstering its immuno-oncology pipelinehttps://pharmaphorum.com/news/boehringer-buys-abexxa-bolstering-its-immuno-oncology-pipeline/
ESMO21: First combo data with Amgen’s Lumakras hit the mark in CRCAmgen has made progress with its plans to expand the use of its first-in-class KRAS inhibitor Lumakras, reporting Share XESMO21: First combo data with Amgen’s Lumakras hit the mark in CRChttps://pharmaphorum.com/news/esmo21-first-combo-data-with-amgens-lumakras-hit-the-mark-in-crc/
Jardiance gets parity with Farxiga in US as FDA clears use in heart failureEli Lilly and Boehringer Ingelheim have claimed FDA approval for their diabetes therapy Jardiance in heart failure with Share XJardiance gets parity with Farxiga in US as FDA clears use in heart failurehttps://pharmaphorum.com/news/jardiance-gets-parity-with-farxiga-in-us-as-fda-clears-use-in-heart-failure/
AZ gets European approvals for Forxiga in chronic kidney diseaseAstraZeneca’s Forxiga has become the first SGLT2 inhibitor to be approved in Europe for use in people with Share XAZ gets European approvals for Forxiga in chronic kidney diseasehttps://pharmaphorum.com/news/az-gets-european-approvals-for-forxiga-in-chronic-kidney-disease/
Boehringer takes alteplase to phase 3 for COVID, but drops antibodyBoehringer Ingelheim’s latecomer antibody therapy for COVID-19 has been side-lined, as the company focuses its attention on its Share XBoehringer takes alteplase to phase 3 for COVID, but drops antibodyhttps://pharmaphorum.com/news/boehringer-takes-alteplase-to-phase-3-for-covid-but-drops-antibody/
Boehringer, Lilly hail Jardiance data in hard-to-treat heart failureBoehringer Ingelheim and Eli Lilly have the results they were hoping for in a large-scale study of Jardiance Share XBoehringer, Lilly hail Jardiance data in hard-to-treat heart failurehttps://pharmaphorum.com/news/boehringer-lilly-hail-jardiance-data-in-hard-to-treat-heart-failure/
AZ closes in Forxiga kidney disease label in EU after nod from CHMPAstraZeneca’s fast-growing SGLT2 inhibitor Forxiga could soon get a further boost from approval in the EU as a Share XAZ closes in Forxiga kidney disease label in EU after nod from CHMPhttps://pharmaphorum.com/news/az-closes-in-forxiga-kidney-disease-label-in-eu-after-nod-from-chmp/
Farxiga faces first heart failure rival as EU OKs Boehringer/Lilly’s JardianceAstraZeneca’s SGLT2 inhibitor Farxiga has been growing fast thanks to a first-in-class approval in heart failure, but will Share XFarxiga faces first heart failure rival as EU OKs Boehringer/Lilly’s Jardiancehttps://pharmaphorum.com/news/farxiga-faces-first-heart-failure-rival-as-eu-oks-boehringer-lillys-jardiance/
Turning words into actions with patient engagementBoehringer Ingelheim’s Carinne Brouillon tells us how the company co-created its recent Global Patient Partnership Summit with patients Share XTurning words into actions with patient engagementhttps://deep-dive.pharmaphorum.com/magazine/market-access-2021/turning-words-into-actions-with-patient-engagement-boehringer-ingelheim/
